Imeth (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, reducing tetrahydrofolate levels needed for DNA synthesis. This limits the production of purine nucleotides and thymidine, impairing DNA replication and cell division, particularly in rapidly proliferating immune cells and tumor cells.

The dosage of Imeth is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and treatment response. Physicians determine the appropriate amount and frequency, and patients should follow the prescribed regimen without alteration.

Imeth is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. It is also not recommended while breastfeeding, as methotrexate can be excreted in milk and affect the infant.

To request Imeth, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Methotrexate is an antimetabolite that directly interferes with DNA synthesis, whereas many other immunosuppressants (e.g., biologic agents) target specific cytokines or cell‑surface receptors. Methotrexate is often less expensive and administered by injection, but it requires regular laboratory monitoring for hepatic and hematologic safety.

Imeth should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial to maintain stability and potency.

Imeth is given as a subcutaneous injection. The healthcare professional selects an appropriate injection site, typically the abdomen or thigh, and administers the prescribed volume using a sterile needle and syringe according to standard aseptic technique.

Serious risks include severe liver toxicity, pulmonary fibrosis, life‑threatening infections due to immunosuppression, bone‑marrow failure (aplastic anemia), and renal failure. Patients should be monitored regularly for signs of these complications, and therapy should be stopped if they occur.

Imeth should not be used by pregnant women, individuals with known hypersensitivity to methotrexate, patients with severe renal or hepatic impairment, those with active infections, or anyone for whom the risk‑benefit profile is unfavorable as determined by their physician.